TrialSignal
Clinical trial intelligence report
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03853044
Status
UNKNOWN
Phase
PHASE2
Sponsor
Ruijin Hospital
Executive brief
Investment-Ready Snapshot
This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03853044
Indication
Angioimmunoblastic T-cell Lymphoma
Modality
small molecule
Target
Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Intervention
Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.